- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05277727
Inflammatory and Immune Response After High Intensity Exercise
Impact of a Novel Marine Algae Supplement on the Inflammatory and Immune Response After High Intensity Exercise
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inflammation is an innate immune response to tissue damage as a means of increasing blood flow to a specific area to facilitate repair, and is associated with the movement of fluid, plasma proteins, and immune cells from the circulation to the site of injury. The inflammatory process is initiated by cytokines which attract specific immune cells, such as monocytes, lymphocytes, neutrophils, and eosinophils, to the damaged tissue. Chronic exercise has been found to reduce inflammation and bolster immune system function; however, acute exercise has been shown to increase inflammatory response. Cytokine secretion and concentrations as well as leukocyte activation following exercise appear to increase in proportion to exercise intensity. Therefore, on an acute basis, high intensity exercise may cause immunosuppression and increased inflammation. High degrees of muscle damage and inflammation post-exercise result in decrements in muscle strength and range of motion, increased delayed onset muscle soreness (DOMS) and swelling, as well as the efflux of myocellular proteins and enzymes, including creatine kinase (CK). Therefore, post-exercise nutritional supplementation for individuals participating in high intensity exercise may be beneficial to modulate exercise-associated immune function and reduce inflammation.
Fucoidans are fucose-rich sulfated carbohydrates found in brown marine algae and have been shown to play a role in immune modulation as well as inflammation. In fact, fucoidans have been shown to inhibit neutrophil infiltration and attenuate levels of pro-inflammatory cytokines. More research is warranted to determine the effects of supplementation with fucoidans to reduce inflammation following high intensity exercise. Therefore, this double-blinded, randomized, placebo-controlled, cross-over design study will be conducted to further understand these effects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Columbia, South Carolina, United States, 29208
- University of South Carolina Sport Science Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fully vaccinated against COVID-19 (participant has received their final dose at least one month prior to the screening visit).
- Individuals who regularly exercise as per physical activity guidelines for Americans10 [structured exercise for a minimum of 150 cumulative minutes per week (low end) to 500 cumulative minutes of exercise per week (high-end)] and willing to maintain the same level of physical activity throughout the study period.
- Healthy individuals between 18 to 40 years of age (inclusive).
- Individuals with BMI in the range of 18.5-34.9 (inclusive).
- Good health as determined by medical history and cleared for exercise as assessed by the PI.
- Male and female participants of reproductive potential should be willing to use double-barrier to avoid pregnancy and sexually transmitted infection (STI) during the study period.
- Provide signed and dated informed consent form.
- Willing and able to comply with the protocol.
Exclusion Criteria:
- Participants with existing musculoskeletal injuries that would prevent full participation.
- History of clinically significant cardiovascular, respiratory, renal, cerebrovascular, metabolic, pulmonary, gastrointestinal, neurological, hematological, autoimmune, lymphatic, psychiatric, hepatobiliary, or endocrine disorders, including individuals with Type I or Type II diabetes, or other clinically significant medical condition that, in the opinion of the PI, may preclude safe study participation.
- Females who are pregnant, lactating, or planning on becoming pregnant during the course of the study.
- Participants using blood thinning medications or supplements.
- Participants having a known sensitivity or allergy to any of the study products or their excipients.
- Participating or has participated in another research study in which another study product has been consumed within 30 days prior to the study screening visit.
- Participants with current or past medical history of long-term COVID-19 symptoms (remained symptomatic for at least 2 weeks or more).
- Professional athletes, collegiate athletes, competitive body builders, or those who compete at the elite category within their sport.
- Participant having any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fucoidan
Fucoidan in Capsule Intervention: Dietary Supplement: Probiotic |
1 capsule to be taken twice daily with food (morning and evening).
|
Placebo Comparator: Placebo
Non active ingredients in a capsule Intervention: Other: Placebo |
1 capsule to be taken twice daily with food (morning and evening).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in CBC panel
Time Frame: After 14 days of supplementation
|
Changes in CBC panel (absolute counts of Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils) compared between two study arms to determine if the TP has an impact compared to placebo
|
After 14 days of supplementation
|
Changes in interleukin-6
Time Frame: After 14 days of supplementation
|
To determine if the TP has an impact on interleukin-6 compared to placebo
|
After 14 days of supplementation
|
Changes in interleukin-1B
Time Frame: After 14 days of supplementation
|
To determine if the TP has an impact on interleukin-1B compared to placebo
|
After 14 days of supplementation
|
Changes in interleukin-10
Time Frame: After 14 days of supplementation
|
To determine if the TP has an impact on interleukin-10 compared to placebo
|
After 14 days of supplementation
|
Changes in T cell
Time Frame: After 14 days of supplementation
|
Monitor changes in T cell subset CD4 and CD8 for TP compared to placebo
|
After 14 days of supplementation
|
Changes in B cell
Time Frame: After 14 days of supplementation
|
Monitor changes in B cell subset CD4 and CD8 for TP compared to placebo
|
After 14 days of supplementation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Outcome Measures
Time Frame: After 14 days of supplementation
|
Adverse events monitoring during the course of study to compare the safety of the TP compared to placebo.
|
After 14 days of supplementation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bridget McFadden, Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M01-21-01-T0011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Response
-
Virginia Polytechnic Institute and State UniversityRecruitingInflammatory ResponseUnited States
-
Utah State UniversityGreenAcres FoundationRecruitingInflammatory ResponseUnited States
-
Assiut UniversityCompleted
-
Norma Osama Abdalla ZayedAbdelhamid, Bassant Mohamed, M.D.CompletedInflammatory ResponseEgypt
-
Ankara City Hospital BilkentNot yet recruitingInflammatory ResponseTurkey
-
Bayside HealthUMC UtrechtActive, not recruiting
-
National Taiwan Normal UniversityCompleted
-
Indonesia UniversityCompletedInflammatory ResponseIndonesia
-
University of ViennaRecruiting
-
University of Southern CaliforniaNot yet recruiting
Clinical Trials on Fucoidan 500mg
-
Taipei Medical University WanFang HospitalAsia UniversityRecruiting
-
University of RochesterNational Cancer Institute (NCI)Not yet recruitingInflammation | FatigueUnited States
-
Hi-Q Marine Biotech International, Ltd.RecruitingAdvanced Hepatocellular CarcinomaChina
-
Hi-Q Marine Biotech International, Ltd.WithdrawnNSCLC Stage IV | NSCLC, Stage IIITaiwan
-
Taipei Medical University WanFang HospitalAsia UniversityRecruiting
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Baxalta now part of ShireCompleted
-
Hiroshima UniversityThree Peace Co., Ltd., JapanCompletedLow Basal Body TemperatureJapan
-
Taipei Medical University WanFang HospitalCompletedNon-alcoholic Fatty Liver DiseaseTaiwan
-
Dong-A ST Co., Ltd.CompletedHealthyKorea, Republic of